Search

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

13.59 -0.66

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.38

Massimo

13.7

Metriche Chiave

By Trading Economics

Entrata

-8.9M

-8M

Vendite

3.7M

139M

P/E

Media del settore

136.6

56.432

Margine di Profitto

-5.724

Dipendenti

1,790

EBITDA

18M

4M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+16.98% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

462M

2.4B

Apertura precedente

14.25

Chiusura precedente

13.59

Notizie sul Sentiment di mercato

By Acuity

50%

50%

120 / 339 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 set 2026, 23:41 UTC

News

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

18 set 2026, 23:31 UTC

News

BlackRock Inc. shares are modestly lower in after-market trading amid heightened legal concerns as the DOJ considers intervention in an antitrust lawsuit against the company.

18 set 2026, 23:26 UTC

News

State Street Corp declines in after-market trading as the U.S. Department of Justice considers intervention in a state antitrust lawsuit regarding energy price inflation.

18 set 2026, 23:16 UTC

News

Union Pacific Corp's stock is trading higher in after-market hours following UBS's upgrade to Buy and a price target increase to $339, citing expected cargo growth.

18 set 2026, 23:11 UTC

News

AutoNation Inc has been downgraded from Buy to Hold amid industry challenges, yet the stock is rising in after-market trading as the broader market advances.

18 set 2026, 23:11 UTC

News

Leidos Holdings Inc. has secured an $85 million contract from the U.S. Department of War for aerospace systems design, with shares rising in after-market trading.

18 set 2026, 23:06 UTC

News

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

18 set 2026, 23:06 UTC

News

Boeing is in talks with NASA to expand its Starliner program, potentially adding ten or more flights, as the stock moves higher in after-hours trading.

18 set 2026, 23:06 UTC

News

Chevron Corp has declined in after-market trading, despite Goldman Sachs raising its price target to $240 and Piper Sandler setting an even higher target of $243.

18 set 2026, 23:06 UTC

News

Okta Inc appointed Helen Riley to its board, enhancing leadership as shares rise in after-market trading, aligning with a broader market advance.

18 set 2026, 23:06 UTC

News
Social Media

Nike shares are advancing in after-market hours despite recent challenges, including a significant decline and hitting a 12-year low.

18 set 2026, 23:06 UTC

News

General Motors Co is advancing in after-market trading following its decision to reinstate Apple’s CarPlay and Android Auto in its vehicles.

18 set 2026, 23:06 UTC

News

Medtronic PLC raised its fiscal 2027 profit forecast and reported first-quarter revenue of $9.756 billion, exceeding expectations, in after-market trading.

18 set 2026, 23:06 UTC

News

RTX Corp's backlog hit a record $289 billion, with the stock advancing in after-market trading, despite remaining below its 20-day moving average.

18 set 2026, 23:06 UTC

News

Celsius Holdings Inc shares are higher in after-market trading, continuing a positive trend despite ongoing legal scrutiny over its Alani Nu product line.

18 set 2026, 23:01 UTC

News
Social Media

Northrop Grumman targets $10 billion in annual international sales by 2031, while shares trade lower in after-market hours.

18 set 2026, 23:01 UTC

News

Kimberly-Clark Corp plans to divest assets related to its $40 billion Kenvue acquisition to address EU antitrust concerns, with shares modestly higher in after-market trading.

18 set 2026, 23:01 UTC

Social Media
News

Accenture PLC announced a $1 billion partnership with Anthropic to enhance AI evaluation capabilities, leading to a sharp advance in shares during after-market hours.

18 set 2026, 23:01 UTC

News

Bitcoin is sharply higher, trading well above its previous close amid a rally in the cryptocurrency market, driven by strong investor sentiment and recent Fed announcements.

18 set 2026, 23:01 UTC

News

Ethereum is advancing sharply, continuing its upward trajectory alongside a broader cryptocurrency rally, despite earlier pulling back from a session high.

18 set 2026, 23:01 UTC

News

Ethereum is advancing sharply, remaining significantly higher since Thursday's close, as the cryptocurrency market rallies alongside Bitcoin surpassing $81k.

18 set 2026, 23:01 UTC

News

Sharply higher amid strong investor sentiment and Fed announcements.

18 set 2026, 23:01 UTC

News
Social Media

Wendy's Co shares are trading modestly higher in after-market hours despite concerns over Meritage Hospitality Group's Chapter 11 bankruptcy filing affecting 314 locations.

18 set 2026, 22:51 UTC

News

Lockheed Martin Corp receives an $871.2 million contract modification for F-35 support, contributing to a modest after-market hours gain.

18 set 2026, 22:51 UTC

News

Hf Foods Group Inc. has terminated its $100 million at-the-market equity offering program, leading to a sharp decline in after-market trading.

18 set 2026, 22:01 UTC

News

Simply Good Foods Co is facing a securities fraud class action lawsuit, contributing to a modest decline in after-market trading following concerns over OWYN's sales performance.

18 set 2026, 21:41 UTC

News

Amneal Pharmaceuticals received FDA approval for its lanreotide injection, launching the product immediately, driving shares higher in after-market hours.

18 set 2026, 21:03 UTC

Macro News
News
Macro Event

The Bank of Japan raised its key interest rate to 1.25%, boosting the USD/JPY pair, which is trading higher above Thursday's close.

18 set 2026, 21:01 UTC

News

Navient Corp is seeing a modest increase in after-market trading, reflecting routine performance and placing the price around the middle of its one-month range.

18 set 2026, 21:01 UTC

News
Macro Event
Correlated Moves

The Bank of Japan raised its key short-term interest rate to 1.25%, causing GBP/JPY to trade modestly higher, though still below its 20-day moving average.

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

16.98% in crescita

Previsioni per 12 mesi

Media 16.167 USD  16.98%

Alto 18.5 USD

Basso 14 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

120 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.